Harvard Medical School Study Validates Opportunity For Urigen Pharmaceuticals' Platform Technology To Develop Treatment For Painful Bladder Syndrome

Main Category: Urology / Nephrology
Also Included In: Pain / Anesthetics
Article Date: 30 Mar 2009 - 3:00 PDT

email to a friend   printer friendly   opinions  

Urigen Pharmaceuticals, Inc. (OTC BB: URGP), a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced that a recent epidemiological study conducted by researchers at the Harvard Medical School has demonstrated that Painful Bladder Syndrome (PBS) is a commonly occurring disorder amongst women, further supporting the Company's focus on developing treatments for the condition.

The study, conducted by KL Lifford and GC Curhan, focused on prevalence rates of the disorder amongst a sample population of older women utilizing the Nurses' Health Study cohort. Participants were mailed a questionnaire inquiring as to the frequency of bladder or pelvic pain associated with urinary symptoms; women who responded indicating symptoms were sent a supplementary questionnaire detailing the severity of those symptoms, results of which were then screened to determine the prevalence of those individuals who reported symptoms consistent with PBS. The study found that 51% of women who responded that they had pain associated with urinary symptoms in the first questionnaire reported symptoms consistent with PBS, representing 2.3% of the total sample population. Of that population, the results demonstrated that the prevalence of PBS was 1.7% in those younger than 65 years of age, increasing progressively to 4% in women age 80 or older. Severity of discomfort reported by patients demonstrating PBS symptoms indicated that the majority of those suffering from the disorder experience moderate to severe discomfort as a result of their condition. The study concluded that PBS is a common condition in women, the prevalence of which increases with age and results in the vast majority of sufferers reporting moderate to severe symptoms.

The study supports Urigen's focus on developing treatments for this painful condition which affects a significant portion of the population, representing a strong, commercially viable market. Urigen's portfolio of products designed to alleviate frequency and severity of symptoms associated with PBS ably position the Company to benefit from the large and growing market demonstrated to exist by the results of this research.

"The results from the Harvard Medical School study further validate our decision to enter this large market. We are excited by the Phase II data we have generated and the supportive intellectual property that has issued. We believe Urigen is well positioned to provide a solution to this problem that affects so many women," said Urigen CEO William Garner, M.D..

About Urigen Pharmaceuticals, Inc.


Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen's two lead programs target significant unmet medical needs and major market opportunities in urology. Urigen's URG101, a proprietary combination of approved drugs that is instilled into the bladder, targets painful bladder syndrome, which affects approximately 10.5 million men and women in North America. Urigen's URG301, a proprietary dosage form of an approved drug that is locally delivered to control urinary urgency, targets acute urgency in females diagnosed with an overactive bladder, another major unmet need that is insufficiently managed by presently available overactive bladder drugs. For further information, please visit Urigen's website at http://www.urigen.com.

Forward-Looking Statement

This press release may contain forward-looking statements. These statements may be identified by the use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. Urigen has based these forward-looking statements on current expectations, assumptions, estimates and projections. While Urigen believes that these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond its control. Given these risks and uncertainties, investors and security holders are cautioned not to place undue reliance on such forward-looking statements. Urigen does not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments.

Source
Urigen Pharmaceuticals, Inc.

• Additional
• References
• Citations